This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
Female patients aged ≥ 18 years at the time of signing the informed consent form.
Histopathologically confirmed diagnosis of cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma).
Stage IIB-IVA disease per the 2018 FIGO staging system.
Presence of measurable lesions as defined by RECIST version 1.1.
Presence of severe concomitant complications (e.g., uncontrolled cardiovascular disease, hypertension, diabetes mellitus, refractory infection, active peptic ulcer, uncontrolled psychiatric disorders, etc.)
Concurrent active second primary malignancy.
Tumour invasion of the rectum (Stage IVA) or peritoneal metastasis (M1).
Prior receipt of immunotherapy agents (including anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.).